Citations

Clear

1820 citation(s) found for "Israel, E".

Efficacy and Safety of Zilucoplan in Amyotrophic Lateral Sclerosis
Fournier, Christina , Quintana, Melanie , Saville, Benjamin R. , Detry, Michelle A. , Vestrucci, Matteo, Marion, Joe , Ajroud‐Driss, Senda , Chase, Marianne, Pothier, Lindsay , Harkey, Brittney, Yu, Hong , Sherman, Alexander , Hall, Meghan, Kittle, Gale, Babu, Suma , Andrews, Jinsy , D’Agostino, Derek, Tustison, Eric, Scirocco, Erica , Alameda, Gustavo, Locatelli, Eduardo, Ho, Doreen , Quick, Adam , Katz, Jonathan, Heitzman, Daragh, Appel, Stanley H., Shroff, Sheetal , Felice, Kevin J. , Maragakis, Nicholas J., Simmons, Zachary , Miller, Timothy M. , Olney, Nicholas , Weiss, Michael D. , Fernandes, Joseph Americo, Jawdat, Omar, Owegi, Margaret, Foster, Laura A. , Ilieva, Hristelina , Newman, Daniel S. , Arcila-Londono, Ximena , Jackson, Carlayne E. , Heiman‐Patterson, Terry , Lewis, Richard A. , Fee, Dominic , Elliott, Matthew, Bedlack, Richard , Kasarskis, Edward J. , Elman, Lauren , Rosenfeld, Jeffrey , Walk, David , McIlduff, Courtney, Twydell, Paul, Young, Eufrosina , Johnson, Kristin, Rezania, Kourosh , Goyal, Namita , Benatar, Michael, Jones, Vovanti , Glass, Jonathan D. , Shah, Jaimin , Beydoun, Said R., Wymer, James , Zilliox, Lindsay , Nayar, Shakti, Pattee, Gary L. , Martinez‐Thompson, Jennifer M. , Patel, Shital , Mahoney, Paul, Duda, Petra W., Group, HEALEY ALS Platform Trial Study, Hayden, Douglas * deceased, Lai, Po-Ying, Donahue, Rachel A., Chen, Hao-Wun, Mathai, Nithya, Lopes, Gabriela, McCaffrey, Alexandra, Scalia, Jennifer , Luppino, Sarah , Lagier‐Tourenne, Clotilde , Sadri‐Vakili, Ghazaleh , Heintzman, Sarah, Sufit, Robert , Szymanski, April, Jenkins, Liberty, Martin, A. D. , Greene, Ericka , Thonhoff, Jason R., Liao, Bing , Whitaker, Charles H. , Clawson, Lora , Uchil, Alpa, Riley, Kristen M., Arneklev, JinAe, Grogan, James , Su, Xiaowei , Mamarabadi, Mansoureh , Malcolm, Amber, Bazan, Tracy, Rad, Nassim, Wang, Leo H. , Piccione, Ezequiel, Thaisetthawatkul, Pariwat , Farmakidis, Constantine , Jabari, Duaa, Pasnoor, Mamatha , Dimachkie, Mazen M. , Brown, Robert H. , Ghasemi, Mehdi, Houmani, Hajar, Douthwright, Catherine, Daniello, Kate, Suresh, Niraja, Farias, Jerrica, Chen, I-Hweii A. , Steijlen, Kara , Bhavaraju‐Sanka, Ratna, Jacobsen, Bill , Milliard, Jourdan, Bowser, Robert , Deboo, Anahita, Cartwright, Michael S. , Nance, Christopher , Yasek, Julia , Harms, Matthew , Burford, Matthew, Shrilla, David, Jones, Sarah , Solórzano, Guillermo, Li, Xiaoyan , Mahuwala, Zabeen , Kumaraswamy, Vishakhadatta Mathur, Baer, Michael , Bhuvaneswaran, Karthikeyan, Maiser, Sam , Rutkove, Seward B. , Mundwiler, Andrew, Meyer, Jenny, Soliven, Betty , Roos, Raymond P. , Habib, Ali A. , Mozaffar, Tahseen , Korb, Manisha Kak , Mullen, Jeffrey, Stommel, Elijah W. , Carberry, Nathan , Govindarajan, Raghav , Darki, Leila, Rodriguez, Rodrigo , McNeely, Whitney, Diaz‐Abad, Montserrat , Jin, Peter H., Chauhan, Chandana, Bobenhouse, James, Staff, Nathan P. , Hayat, Ghazala , Bailey, Abbey, Bailey, Jesse, Barlow, Victoria , Bulat, Allison, Changkuon, Genevive, Cirino, Melissa, Deignan, Cristina, Deirmendjian, Emma, Mattos, Annette De, DiStefano, Sofia, Drake, Kristin, Estes, Michaela, Faulconer, Kenneth, Figueroa-Szostek, Precious, Garozzo, Tessa, Hasenoehrl, Meredith Gibbons, Henrique, Jennifer, Henrique, Natalie, Hurwitz, Samuel , Igne, Courtney, Irwin, L. R., Jentoft, Katie, Jordan, Boglarka, Katsovskiy, Igor, Kharakozova, Olga, Kolvek, Taylor, Korin, Alexander, La, Thuong, Li, Haining , Nguyen, Joey, Novak, Ilya, Ortiz, Ricardo, Ostrow, Joe, Pagliaro, Jaclyn , Palillo, Jack, Patel, Payal , Patterson, Janae, Phan, Minh , Popel, Najla , Proueng, Serena, Rosenthal, Jesse, Small, Catherine B. , Tarasenko, Natalia, Thomas, Mirna, Vigneswaran, Prasha, Wahab, Yusra, Whitworth, Isaac, Wright, Spencer, Connolly, Mariah, Santiago, Diana De, Felix, A. John William , Garrett, Karly, Hamilton, Jenny, Khan, Kamran , Lovett, Marlee, Nelson, Linda S., Pabon, Marissa, Rede, Diana, Bolger, Patrick, Fetouh, Ahmed , Woodcook, Joan, Kamp, Cornelia , Kennedy, Julie, McGarry, Andrew , Torti, Margherita , Maragakis, Nicholas J. , Martinez-Thompson, Jennifer, Scirocco, Erica , Simmons, Zachary , Staff, Nathan P , Maragakis, Nicholas , Bedlack, Richard S , Dimachkie, Mazen M , Walk, David , Paganoni, Sabrina , Macklin, Eric A. , Chibnik, Lori Beth , McGlothlin, Anna , Shefner, Jeremy M. , Berry, James D. , Giacomelli, Elisa , Appel, Stanley H. , Goutman, Stephen A. , Fernandes, J. Americo, Vu, Tuan , Newman, Daniel S., Ladha, Shafeeq , Caress, James B. , Swenson, Andrea , Peltier, Amanda , Johnson, Kristin, Cohen, Jeffrey Allen , Harvey, Brittany, Mahoney, Paul, Cudkowicz, Merit , Group, HEALEY ALS Platform Trial Study, Hayden, Douglas * deceased, Donahue, Rachel A., Chen, Hao-Wun, Wang, Jianing, Mathai, N. M., Kolb, Stephen J. , Szymanski, April, Martin, Alan, Liao, Bing, Riley, Kristen M., Malcolm, Amber, Feldman, Eva L. , Statland, Jeffrey , Ghasemi, Mehdi , Pasinelli, Piera , Gutmann, Ludwig , Harms, Matthew B. , Diaz, Frank , Rakočević, Goran , Quinn, Colin , Borg, David, Kaur, Jasdeep, Rao, Pooja, Robbins, Nathaniel M. , Granit, Volkan , Oskarsson, Björn , Chuquilin, Miguel , Arroyave, Luisa, Bailey, Abbey, Bulat, Allison , Hurwitz, Samuel, Irwin, Liam, Jordan, Boglarka, Korin, Alexander, Novak, Ilya, Patterson, Janae, Phan, Minh, Rosenthal, Jesse, Small, Catherine, Thomas, Mirna, Wahab, Yusra, Wright, Spencer, Garrett, Karly, Lovett, Marlee, Nelson, Linda, Pabon, Marissa, Bolger, Patrick, Fetouh, Ahmed, Kennedy, Julie

Mayo Clinic

JAMA Network Open | February 17, 2025 | Volume: 8 | Issue: 2 | Pages: e2459058

10.1001/jamanetworkopen.2024.59058 | PMID 39960672 Get It

Importance The etiology of amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease, is unknown. However, neuroinflammation and complement activation may play a role in disease progression. Objective To determine the effects of zilucoplan, an inhibitor of complement C5, in individuals with ALS. Design, Setting, and Participants Zilucoplan was tested as regimen A of the HEALEY ALS Platform Trial, a phase 2 to 3 multicenter, randomized, double-blind, placebo-controlled perpetual platform clinical trial with sharing of trial infrastructure and placebo data across multiple regimens. Regimen A was conducted from August 17, 2020, to May 4, 2022. A total of 162 participants were randomized to receive zilucoplan (122 [75.3%]) or regimen-specific placebo (40 [24.7%]). An additional 124 concurrently randomized participants were randomized to receive placebo in other regimens. Interventions Eligible participants were randomized in a 3:1 ratio to receive zilucoplan or matching placebo within strata of edaravone and/or riluzole use for a planned duration of 24 weeks. Active drug (zilucoplan, 0.3 mg/kg) and placebo were provided for daily subcutaneous dosing. Main Outcomes and Measures The primary end point was change in disease severity from baseline through 24 weeks as measured by the Amyotrophic Lateral Sclerosis Functional Rating Scale–Revised (ALSFRS-R) total score and survival, analyzed using a bayesian shared-parameter model and reported as disease rate ratio (DRR; <1 indicating treatment benefit). The study included prespecified rules for early stopping for futility. Outcome analyses were performed in the full analysis set comparing the zilucoplan group with the total shared placebo group (n = 164). Results Among the 162 participants who were randomized (mean [SD] age, 59.6 [11.3]; 99 [61.1%] male), 115 (71.0%) completed the trial. The estimated DRR common to ALSFRS-R and survival was 1.08 (95% credible interval, 0.87-1.31; posterior probability of superiority, 0.24). The trial was stopped early for futility. No unexpected treatment-related risks were identified. Conclusions and Relevance In this randomized clinical trial of zilucoplan in ALS, treatment did not alter disease progression. The adaptive platform design of the HEALEY ALS Platform Trial made it possible to test a new investigational product with efficient use of time and resources. Trial Registration ClinicalTrials.gov Identifier: NCT04297683
CNM-Au8 in Amyotrophic Lateral Sclerosis
Hayden, Douglas, Lai, Po-Ying, Donahue, Rachel, Chen, H., Mathai, N. M., Lopes, Gabriela, McCaffrey, Alexandra, Scalia, Jennifer , Luppino, Sarah , Lagier‐Tourenne, Clotilde , Sadri‐Vakili, Ghazaleh , Heintzman, Sarah, Sufit, Robert , Szymanski, April, Jenkins, Liberty, Martin, A. D. , Greene, Ericka , Thonhoff, Jason R., Liao, Bing , Whitaker, Charles H. , Clawson, Lora , Uchil, Alpa, Riley, Kristen M., Arneklev, JinAe, Grogan, James , Su, Xiaowei , Mamarabadi, Mansoureh , Malcolm, Amber, Bazan, Tracy, Rad, Nassim, Wang, Leo H. , Piccione, Ezequiel, Thaisetthawatkul, Pariwat , Farmakidis, Constantine , Jabari, Duaa, Pasnoor, Mamatha , Brown, Robert H. , Houmani, Hajar, Douthwright, Catherine, Daniello, Kate, Suresh, Niraja, Farias, Jerrica, Chen, I-Hweii A. , Steijlen, Kara , Bhavaraju‐Sanka, Ratna, Jacobsen, Bill , Milliard, Jourdan, Bowser, Robert , Deboo, Anahita, Cartwright, Michael S. , Nance, Christopher , Yasek, Julia , Harms, Matthew, Burford, Matthew, Shrilla, David, Jones, Sarah, Solórzano, Guillermo, Mahuwala, Zabeen , Kumaraswamy, Vishakhadatta Mathur, Baer, Michael , Bhuvaneswaran, Karthikeyan, Maiser, Sam , Mundwiler, Andrew, Meyer, Jenny, Roos, Raymond P. , Habib, Ali A. , Mozaffar, Tahseen , Korb, Manisha Kak , Carberry, Nathan , Govindarajan, Raghav , Fournier, Christina , Darki, Leila, Rodriguez, Rodrigo , Chuguilin, Miguel, McNeely, Whitney, Diaz‐Abad, Montserrat , Jin, Peter H., Chauhan, Chandana, Bobenhouse, James, Staff, N., Hayat, Ghazala , Bailey, Abbey, Bailey, Jesse, Barlow, Victoria , Bulat, Allison , Changkuon, Genevive, Cirino, Melissa, Deignan, Cristina, Deirmendjian, Emma, Mattos, Annette De, DiStefano, Sofia, Drake, Kristin, Estes, M L, Faulconer, Kenneth, Figueroa-Szostek, Precious, Garozzo, Tessa, Hasenoehrl, Meredith Gibbons, Henrique, Jennifer, Henrique, Natalie, Hurwitz, Samuel , Igne, Courtney, Irwin, L. R., Jentoft, Katie, Jordan, Boglarka, Katsovskiy, Igor, Kharakozova, Olga, Kolvek, Taylor, Korin, Alexander, La, Thuong, Nguyen, Joey, Novak, Ilya, Ortiz, Ricardo, Ostrow, Joe, Pagliaro, Jaclyn , Palillo, Jack, Patterson, Janae, Phan, Minh, Popel, Najla , Proueng, Serena, Rosenthal, Jesse, Small, Catherine B. , Tarasenko, Natalia, Thomas, Mirna, Vigneswaran, Prasha, Wahab, Yusra, Whitworth, Isaac, Wright, Spencer, Connolly, Mariah, Santiago, Diana De, Félix, Adrián, Garrett, Karly, Hamilton, Jenny, Lovett, Marlee, Nelson, Linda S., Pabón, M. Vargas, Rede, Diana, Bolger, Patrick, Fetouh, Ahmed , Woodcook, Joan, Kamp, Cornelia , Kennedy, Julie, McGarry, Andrew , Torti, Margherita , Maragakis, Nicholas J. , Quintana, Melanie , Saville, Benjamin R. , Detry, Michelle A. , Vestrucci, Matteo, Marion, Joseph , Stommel, Elijah W. , Chase, Marianne, Pothier, Lindsay , Harkey, Brittney, Yu, Hong , Sherman, Alex, Hall, Meghan, Kittle, Gale, Babu, Suma , Andrews, Jinsy , D’Agostino, Derek, Tustison, Eric, Scirocco, Erica, Alameda, Gustavo, Locatelli, Eduardo, Ho, Doreen , Quick, Adam , Ajroud‐Driss, Senda , Katz, Jonathan, Heitzman, Daragh, Appel, Stanley H. , Shroff, Sheetal , Felice, Kevin J. , Simmons, Zachary, Miller, Timothy M. , Olney, Nicholas , Weiss, Michael D. , Fernandes, Joseph Americo, Jawdat, Omar, Owegi, Margaret, Foster, Laura A. , Ilieva, Hristelina , Newman, Daniel S. , Arcila-Londono, Ximena , Jackson, Carlayne E. , Heiman‐Patterson, Terry , Lewis, Richard A. , Fee, Dominic , Elliott, Matthew , Bedlack, Richard , Kasarskis, Edward J. , Elman, Lauren , Rosenfeld, Jeffrey V. , Walk, David , McIlduff, Courtney, Twydell, Paul, Young, Eufrosina , Johnson, Kristin, Rezania, Kourosh , Goyal, Namita , Benatar, Michael, Jones, Vovanti , Glass, Jonathan D. , Shah, Jaimin , Beydoun, Said R., Wymer, James , Zilliox, Lindsay , Nayar, Shakti, Pattee, Gary L. , Martinez‐Thompson, Jennifer M. , Rynders, Austin, Evan, Jacob, Evan, Jeremy, Hartford, Alan , Sepassi, Marjan , Ho, Karen S. , Glanzman, Robert , Hotchkin, Michael T. , Group, HEALEY ALS Platform Trial Study, Simmons, Zachary , Scirocco, Erica , Martinez-Thompson, Jennifer, Scirocco, Erica , Simmons, Zachary , Maragakis, Nicholas , Bedlack, Richard S , Walk, David , Wang, Jianing , Kolb, Stephen J. , Szymanski, April L., Martin, Alan, Liao, Bing, Arneklev, JinAe, Malcolm, Amber, Feldman, Eva L. , Statland, Jeffrey , Dimachkie, Mazen M. , Ghasemi, Mehdi , Houmani, Hajar, Pasinelli, Piera , Milliard, Jourdan, Gutmann, Ludwig , Harms, Matthew, Diaz, Frank , Shrilla, David, Rakočević, Goran , Li, Xiaoyan , Quinn, Colin , Borg, David, Bhuvaneswaran, Karthikeyan, Kaur, Jasdeep, Rutkove, Seward B. , Rao, Pooja, Mullen, Jeffrey, Robbins, Nathaniel M. , Granit, Volkan , Oskarsson, Björn , McNeely, Whitney, Bobenhouse, James, Arroyave, Luisa, Changkuon, Genevive, Cirino, Melissa, Deignan, Cristina, Deirmendjian, Emma, Estes, Michaela, Figueroa-Szostek, Precious, Garozzo, Tessa, Henrique, Jennifer, Henrique, Natalie, Hurwitz, Samuel, Irwin, Liam, Kolvek, Taylor, Korin, Alexander, Li, Haining, Nguyen, Joey, Ostrow, Joe, Palillo, Jack, Patel, Payal , Proueng, Serena, Rosenthal, Jesse, Small, Catherine, Thomas, Mirna, Santiago, Diana De, Felix, Adrian, Garrett, Karly, Khan, Kamran, Nelson, Linda, Rede, Diana, Bolger, Patrick, Fetouh, Ahmed, Woodcook, Joan, Kennedy, Julie, Berry, James D. , Macklin, Eric A. , Chibnik, Lori Beth , McGlothlin, Anna , Shefner, Jeremy M. , Giacomelli, Elisa , Goutman, Stephen A. , Fernandes, J. Americo, Vu, Tuan , Newman, Daniel S., Ladha, Shafeeq , Caress, James B. , Swenson, Andrea , Peltier, Amanda , Elliott, Matthew, Johnson, Kristin, Cohen, Jeffrey Allen , Greenberg, Benjamin , Paganoni, Sabrina , Cudkowicz, Merit

Mayo Clinic

JAMA | February 17, 2025 | Volume: 333 | Issue: 13 | Pages: 1138

10.1001/jama.2024.27643 | PMID 40067821 Get It

Importance Bioenergetic failure has been proposed as a driver of amyotrophic lateral sclerosis (ALS). CNM-Au8 is a suspension of gold nanocrystals that catalyzes the conversion of nicotinamide adenine dinucleotide hydride into NAD + , resulting in an increase of cellular adenosine triphosphate production. Objective To determine the effects of CNM-Au8 on ALS disease progression. Design, Setting, and Participants CNM-Au8 was tested as a regimen of the HEALEY ALS Platform Trial, a phase 2/3, multicenter, randomized, double-blind platform trial. The study was conducted at 54 sites in the US from July 2020 to March 2022 (final follow-up, March 17, 2022). A total of 161 participants with ALS were randomized to receive CNM-Au8 (n = 120) or regimen-specific placebo (n = 41). Data from 123 concurrently randomized placebo participants in other regimens were combined for analyses. Interventions Eligible participants were randomized in a 3:3:2 ratio to receive CNM-Au8 60 mg daily (n = 61), CNM-Au8 30 mg daily (n = 59), or matching placebo (n = 41) for 24 weeks. Main Outcomes and Measures The primary efficacy outcome was change from baseline through week 24 in ALS disease severity measured by a bayesian shared parameter model of function (based on the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale) and survival, which provided an estimate of the rate of disease progression measured by the disease rate ratio (DRR), with a DRR of less than 1 indicating treatment benefit. Secondary end points included a Combined Assessment of Function and Survival using a joint-rank test, rate of decline in slow vital capacity (percent predicted), and survival free of permanent assisted ventilation. Results Among 161 participants who were randomized within the CNM-Au8 regimen (mean age, 58.4 years; 61 [37.9%] female), 145 (90%) completed the trial. In the primary analysis comparing the combined CNM-Au8 dosage groups vs the combined placebo groups, the primary end point (DRR, 0.97 [95% credible interval, 0.783-1.175]; posterior probability of DRR <1, 0.65) and the 3 secondary end points suggested no benefit or harm of CNM-Au8. In the active (n = 120) vs placebo (n = 163) groups, the most common adverse events were diarrhea (23 [19%] vs 12 [7%]), nausea (17 [14.2%] vs 14 [8.6%]), fatigue (12 [10.8%] vs 30 [18.4%]), and muscular weakness (24 [20%] vs 45 [27.6%]). Conclusions and Relevance No benefit of CNM-Au8 on ALS disease progression was observed at 24 weeks. Trial Registration ClinicalTrials.gov Identifiers: NCT04297683 , NCT04414345
Impact of Admission Ward on Long-Term Outcomes in Patients with Non-ST Elevation Myocardial Infarction
Bartal, Carmi , Hilu, Ranin , Alsana, Hadel , Peles, Ido , Tsaban, Gal , Merkin, Miri , Rosenstein, Gabriel, El-Nasasra, Aref, Shmueli, Hezzy , Abramowitz, Yigal, Cafri, Carlos, Zahger, Doron , Koifman, Edward , Zagher, Doron

Mayo Clinic

Journal of Clinical Medicine | February 17, 2025 | Volume: 14 | Issue: 4 | Pages: 1284

10.3390/jcm14041284 | PMID 40004814 Get It

Background: Patients presenting with non-ST elevation myocardial infarction (NSTEMI) are often admitted to medical wards. We aimed to evaluate the impact of the admitting department on long-term outcomes. Methods: Patients admitted to a large tertiary center were categorized according to the admission ward, either the intensive cardiac care unit (ICCU) or internal medicine department (IMD). We compared major adverse cardiovascular events (MACEs), a composite of all-cause death, recurrent myocardial infarction (MI), and revascularization, along with the individual components of MACE, between the two groups during a long-term follow-up. Results: A total of 11,779 NSTEMI patients were included, with 4522 admitted to the ICCU and 7257 to the department of internal medicine. Patients admitted to the ICCU had lower systolic blood pressure, higher troponin levels and lower left ventricular ejection fraction (LVEF) compared to those in the IMD group, indicating greater initial clinical severity. Although patients admitted to the ICCU experienced a significantly higher rate of in-hospital complications, there were no significant differences in the incidence of in-hospital deaths between the two groups. During 5-year follow-up, NSTEMI patients initially admitted to the ICCU had significantly lower rates of mortality and MACEs. The estimated hazard ratio for 5-year MACE and 5-year mortality rates for NSTEMI patients admitted to the IMD vs. those admitted to the ICCU were 2.03 (95% CI, 1.04–3.34) and 2.5 (95% CI, 1.10–4.38), respectively. Conclusions: NSTEMI patients admitted to the ICCU experienced lower long-term mortality and MACE rates. These findings support the management of NSTEMI patients in cardiac wards and warrant further research into the reasons for the improved outcome.
Outcomes of arteriovenous malformation patients with multiple versus single feeders: A multicenter retrospective study with propensity-score matching
Musmar, Basel , Adeeb, Nimer , Abdalrazeq, Hammam , Tjoumakaris, Stavropoula I, Salim, Hamza , Kondziolka, Douglas, Sheehan, Jason P. , Ogilvy, Christopher S. , Riina, Howard A. , Naamani, Kareem El, Ironside, Natasha , Ataoglu, Cagdas , Keleş, Abdullah , Muram, Sandeep , Sconzo, Daniel , Rezai, Arwin, Alwakaa, Omar , Erginoğlu, Ufuk , Sen, Rajeev , Griessenauer, Christoph J., Burkhardt, Jan-Karl, Starke, Robert M., Başkaya, Mustafa K. , Levitt, Michael R, Altschul, David , McAvoy, Malia , Aslan, Assala , Abushehab, Abdallah, Swaid, Christian, Abla, Adib A. , Sizdahkhani, Saman , Koduri, Sravanthi , Atallah, Elias , Karadimas, Spyridon, Gooch, M Reid, Rosenwasser, Robert H. , Stapleton, Christopher J. , Koch, Matthew J. , Srinivasan, Visish M. , Cochran, Joseph, Pukenas, Bryan , Smith, Edward, Patel, Aman B. , Cuellar, Hugo H, Lawton, Michael T. , Guthikonda, Bharat , Ogilvy, Christopher S. , Alaraj, Ali , Smith, Edward R. , Salim, Hamza , Essibayi, Muhammed Amir , Alwakaa, Omar , Mosimann, Pascal J , Jabbour, Pascal , Alaraj, Ali , Abla, Adib , Altschul, David J , Musmar, Basel , Ogilvy, Christopher S , Keles, Abdullah , Erginoglu, Ufuk , Smith, Edward , Burkhardt, Jan‐Karl , Roy, Joanna M. , Tjoumakaris, Stavropoula , Kandregula, Sandeep , Dmytriw, Adam A. , Naamani, Kareem El , Abdelsalam, Ahmed , Kumbhare, Deepak , Essibayi, Muhammed Amir , Rezai, Arwin, Tos, Salem M , Pöppe, Johannes , Sen, Rajeev D, Griessenauer, Christoph J. , Sekhar, Laligam N. , Karadimas, Spyridon K. , Gooch, Michael Reid , Chen, Peng R , Blackburn, Spiros , Choudhri, Omar , Orbach, Darren B. , Aziz‐Sultan, Mohammad Ali , Morcos, Jacques J. , Jabbour, Pascal

Mayo Clinic

European Stroke Journal | February 15, 2025 | Volume: 10 | Issue: 3 | Pages: 946-960

10.1177/23969873251319924 | PMID 39953956 Get It

Abstract Introduction The impact of multiple feeding arteries on clinical outcomes of cerebral arteriovenous malformations (AVMs) is not well understood. This study aims to compare outcomes between AVMs with multiple versus single feeding arteries. Patients and Methods Data from the Multicenter International Study for Treatment of Brain AVMs (MISTA) consortium were analyzed. Propensity score matching (PSM) was used to balance cohorts. Subgroup analysis was conducted for ruptured and unruptured AVMs and different treatment options, and multivariable logistic regression was applied to assess the impact of feeding artery origin. Results Among 953 patients, 661(69.4%) had multiple feeding arteries, and 292 (30.6%) had a single feeding artery. After PSM, which included 422 matched patients (211 in each group), the differences in obliteration rates (68.7% vs 74.8%, OR 0.73, 95% CI: 0.48–1.12, p = 0.16) and symptomatic complications (15.6% vs 11.8%, OR 1.37, 95% CI: 0.78–2.41, p = 0.25) were not significant. Subgroup analysis comparing ruptured and unruptured AVMs and different treatment options showed no significant differences across all subgroups. Multivariable analysis identified PICA feeders as significantly associated with increased odds of all complications (OR 7.33, 95% CI: 2.14–25.1, p = 0.002). Discussion and Conclusion AVMs with a single feeding artery were more likely to present with rupture, but no significant differences in obliteration rates or complications were observed between the groups after PSM. These findings suggest that while the number of feeding arteries may influence the initial presentation, it does not appear to impact overall treatment success or patient prognosis. Further prospective studies are needed to confirm these findings.
Comparative outcomes of arteriovenous malformations treatment in eloquent versus non-eloquent brain: A multicenter study with propensity-score weighting
Adeeb, Nimer , Abdalrazeq, Hammam , Salim, Hamza , Aslan, Assala , Tjoumakaris, Stavropoula I, Ogilvy, Christopher S. , Başkaya, Mustafa K. , Kondziolka, Douglas, Sheehan, Jason P. , Riina, Howard A. , Abushehab, Abdallah, Naamani, Kareem El, Ironside, Natasha , Gummadi, Sanjeev, Ataoglu, Cagdas , Keleş, Abdullah , Muram, Sandeep , Sconzo, Daniel , Rezai, Arwin, Alwakaa, Omar , Park, Min S. , Erginoğlu, Ufuk , Sen, Rajeev , Griessenaur, Christoph, Burkhardt, Jan‐Karl , Starke, Robert M., Sekhar, Laligam N., Altschul, David , Haranhalli, Neil , McAvoy, Malia , Zeineddine, Hussein A. , Abla, Adib A. , Atallah, Elias , Rosenwasser, Robert H. , Stapleton, Christopher J. , Koch, Matthew, Srinivasan, Visish M. , Bulsara, Ketan R., Kim, Louis J. , Pukenas, Bryan , Smith, Edward R. , Alaraj, Ali , Patel, Aman B. , Notarianni, Christina , Lawton, Michael T. , Guthikonda, Bharat , Salim, Hamza , Dmytriw, Adam A , Levitt, Michael R , Chen, Peng R , Alaraj, Ali , Guthikonda, Bharat , Jabbour, Pascal , Abla, Adib , Altschul, David J , Ogilvy, Christopher S , Alwakaa, Omar , Keles, Abdullah , Erginoglu, Ufuk , Smith, Edward , Burkhardt, Jan‐Karl , Musmar, Basel , Roy, Joanna M. , Tjoumakaris, Stavropoula , Kandregula, Sandeep , Dmytriw, Adam A. , Naamani, Kareem El , Abdelsalam, Ahmed , Kumbhare, Deepak , Essibayi, Muhammed Amir , Tos, Salem M , Mantziaris, Georgios , Hanalıoğlu, Şahin , Pöppe, Johannes , Sen, Rajeev D, Griessenauer, Christoph J. , Sekhar, Laligam N. , Levitt, Michael R. , Gooch, Michael Reid , Koch, Matthew J. , Blackburn, Spiros , Kim, Louis J. , Choudhri, Omar , Mosimann, Pascal J , Aziz‐Sultan, Mohammad Ali , Savardekar, Amey Rajan , Cuellar, Hugo , Morcos, Jacques J. , Jabbour, Pascal

Mayo Clinic

International Journal of Stroke | February 14, 2025 | Volume: 20 | Issue: 7 | Pages: 852-863

10.1177/17474930251323503 | PMID 39948730 Get It

Background: Arteriovenous malformations (AVMs) are complex vascular anomalies with a high risk of hemorrhage and neurological deficits, especially when located in eloquent brain regions. The eloquence of an AVM location is a critical factor in the treatment planning, influencing both the risk of complications and long-term functional outcomes. This study aims to compare outcomes between eloquent and non-eloquent AVMs. Methods: This multicenter, retrospective study utilized data from the Multicenter International Study for Treatment of Brain AVMs (MISTA) consortium. Patients with eloquent and non-eloquent AVMs were compared on baseline characteristics, angiographic outcomes, and functional outcomes using the modified Rankin Scale (mRS). Propensity score weighting (IPTW) was applied to adjust for confounding variables. Results: The study included 1013 patients, with 498 (49.2%) AVMs located in eloquent regions and 515 (50.8%) in non-eloquent regions. In unadjusted analysis, eloquent AVMs had lower complete obliteration rates (67.6% vs 79.5%, OR: 0.53, 95% CI: 0.39–0.72, p < 0.001) and higher complication rates (24.5% vs 19.0%, OR: 1.38, 95% CI: 1.02–1.86, p = 0.03) compared to non-eloquent AVMs. After IPTW adjustment, eloquent AVMs continued to show significantly higher odds of overall complications (OR: 1.68, 95% CI: 1.12–2.52, p = 0.01) and symptomatic complications (OR: 1.77, 95% CI: 1.12–2.80, p = 0.01). Secondary analysis within the eloquent group indicated that embolization was linked to an elevated risk of complications. Surgery and radiosurgery showed comparable functional outcomes at last follow-up and complications rates with higher complete obliteration rates in surgery. Conclusion: AVMs in eloquent brain areas present higher risks of complications and lower obliteration rates, emphasizing the need for cautious, individualized treatment planning. Within the eloquent group, embolization increased the risk of complications, while surgery and radiosurgery showed comparable functional outcomes at last follow-up and complication rates with higher complete obliteration rates in surgery. These findings highlight the importance of location in AVM management and support further research focusing on comparing treatment strategies for AVMs in eloquent brain areas.
Capacity assessment for EHR-based medical device post-market surveillance for synthetic mid-urethral slings among women with stress urinary incontinence: a NEST consortium study
Matheny, Michael E. , Perkins, Amy M. , Rieger‐Christ, Kimberly , Ross, Joseph S. , Mao, Jialin , Sedrakyan, Art , Shah, Nilay D. , Mourtzinos, Arthur, Bartlett, Victoria , Solotke, Michael T. , Pandya, Sameer, Aryal, Suvekshya , Cho, Ahra, Frankenberger, Edward , Park, Daniel , Bostrom, Danielle, Robbins, Susan P. , Yustein, Aron, Trabuco, Emanuel C. , Frankenberger, Edward A , Chughtai, Bilal , Trabuco, Emanuel C , Matheny, Michael , Ross, Joseph S , Winter, Robert, Reynolds, William M. , Schulz, Wade L. , Robbins, Susan, Yustein, Aron S.

Mayo Clinic

BMJ Surgery, Interventions, & Health Technologies | February 12, 2025 | Volume: 7 | Issue: 1 | Pages: e000193

10.1136/bmjsit-2023-000193 | PMID 39949784 Get It

Objectives To evaluate the feasibility for use of electronic health record (EHR) data in conducting adverse event surveillance among women who received mid-urethral slings (MUS) to treat stress urinary incontinence (SUI) in five health systems. Design Retrospective observational study using EHR data from 2010 through 2021. Women with a history of MUS were identified using common data models; a common analytic code was executed at each site. A manual chart review was conducted in a per-site random patient subset to establish a reference standard. Automated text processing (Text Processed Integrated (TPI)) was developed and evaluated at each site to determine the surgical approach and synthetic mesh implantation. Patients were characterized and surgical outcomes were ascertained over 730 subsequent days. Setting Five large tertiary care academic medical centers. Participants Across five health systems, 9,906 eligible patients (mean age 57–60 per site) were identified. Main outcome measures Determination of surgical approach, synthetic mesh implantation, and assessment of the duration of surveillance for mortality and reoperation rates following MUS implantation. Results In the TPI cohort analysis, 3,331 patients were identified. Surgical approach per site was retropubic (42% to 77%), transobturator (6% to 44%), single incision (0% to 24%), and adjustable sling (0% to <4%). Concordance rates for TPI using chart review were 71%–90% at each site for the surgical approach and 28%–85% for synthetic mesh implantation. Patient follow-up observation rates for mortality and reoperation ranged from 22% to 36% at 90 days, 15% to 30% at 365 days, and 8% to 19% at 730 days. Conclusion Using EHR data alone, identification of medical devices and surgical approaches was feasible among women with MUS surgery for SUI, but long-term follow-up ascertainment rates were low. Medical device surveillance using EHR data should be evaluated in the context of the clinical use case, as applicability may vary.
Efficacy and safety of preoperative embolization in surgical treatment of brain arteriovenous malformations: a multicentre study with propensity score matching
Salim, Hamza , Hamdan, Dawoud, Adeeb, Nimer , Aslan, Assala , Musmar, Basel , Ogilvy, Christopher S. , Dmytriw, Adam A. , Ataoglu, Cagdas , Erginoğlu, Ufuk , Naamani, Kareem El, Sheehan, Jason P. , Ironside, Natasha , Gummadi, Sanjeev, Keleş, Abdullah , Muram, Sandeep , Sconzo, Daniel , Rezai, Arwin, Alwakaa, Omar , Sen, Rajeev , Başkaya, Mustafa K. , Tjoumakaris, Stavropoula , Atallah, Elias , Riina, Howard A. , Abushehab, Abdallah, Swaid, Christian, Burkhardt, Jan‐Karl , Starke, Robert M., Altschul, David , Haranhalli, Neil , McAvoy, Malia , Abla, Adib A. , Stapleton, Christopher J. , Koch, Matthew J. , Srinivasan, Visish M. , Cochran, Joseph, Pukenas, Bryan , Smith, Edward R. , Moehlenbruch, Markus, Alaraj, Ali , Patel, Aman B. , Yedavalli, Vivek , Cuellar, Hugo H, Lawton, Michael T. , Guthikonda, Bharat , Aslan, Assala , Musmar, Basel , Ogilvy, Christopher S , Dmytriw, Adam A , Essibayi, Muhammed Amir , Alwakaa, Omar , Griessenauer, Christoph J , Jabbour, Pascal , Altschul, David J , Koch, Matthew J , Chen, Peng R , Orbach, Darren B , Alaraj, Ali , Yedavalli, Vivek S , Abla, Adib , Salim, Hamza , Keles, Abdullah , Erginoglu, Ufuk , Smith, Edward , Hamdan, Dawoud , Kandregula, Sandeep , Abdelsalam, Ahmed , Kondziolka, Douglas , Naamani, Kareem El , Kumbhare, Deepak , Essibayi, Muhammed Amir , Tos, Salem M , Rezai, Arwin, Pöppe, Johannes , Sen, Rajeev D, Griessenauer, Christoph J. , Jabbour, Pascal , Sekhar, Laligam N. , Levitt, Michael R. , Blackburn, Spiros , Choudhri, Omar , Orbach, Darren B. , Mosimann, Pascal J , Aziz‐Sultan, Mohammad Ali , Wintermark, Max , Savardekar, Amey Rajan , Morcos, Jacques J.

Mayo Clinic

Journal of Neurology, Neurosurgery & Psychiatry | February 6, 2025 | Volume: 96 | Issue: 8 | Pages: 766-774

10.1136/jnnp-2024-334974 | PMID 39915091 Get It

Background Brain arteriovenous malformations (AVMs) are abnormal connections between feeding arteries and draining veins, associated with significant risks of haemorrhage, seizures and other neurological deficits. Preoperative embolization is commonly used as an adjunct to microsurgical resection, with the aim of reducing intraoperative complications and improving outcomes. However, the efficacy and safety of this approach remain controversial. Methods This study is a subanalysis of the Multicenter International Study for Treatment of Brain AVMs consortium. We retrospectively analysed 486 patients with brain AVMs treated with microsurgical resection between January 2010 and December 2023. Patients were divided into two groups: those who underwent microsurgery alone (n=245) and those who received preoperative embolization, followed by microsurgery (n=241). Propensity score matching was employed, resulting in 288 matched patients (144 in each group). The primary outcomes were rates of complete AVM obliteration and functional outcomes (measured by the modified Rankin Scale (mRS)). Secondary outcomes included complication rates, mortality, hospital length of stay and postsurgical rupture. Results After matching, the complete obliteration rate was 97% with no significant difference between the microsurgery-only group and the preoperative embolization group (p=0.12). The proportion of patients with an mRS score of 0–2 at the last follow-up was similar in both groups (83% vs 84%; p=0.67). The median hospital stay was significantly longer for the embolisation group (9 days vs 7 days; p=0.017). Complication rates (24% vs 22%; p=0.57) and mortality rates (4.9% vs 2.1%; p=0.20) were comparable between the two groups. No significant differences were observed in postsurgical rupture, recurrence or retreatment rates. Conclusions In this large multicentre study, preoperative embolization did not significantly improve AVM obliteration rates, functional outcomes or reduce complications compared with microsurgery alone.
Characterization of the Cystic Phenotype Associated with Monoallelic ALG8 and ALG9 Pathogenic Variants
Jawaid, Tabinda , Elbarougy, Doaa E. , Lavu, Sravanthi , Buia, Guillaume, Senum, Sarah R. , Olinger, Eric , Yang, Hana , Bublitz, Joshua T., Ma, Jun , Audrézet, Marie‐Pierre , Madsen, Charles D. , Schauer, R., Baker, Tracy A. , Gregory, Adriana , Orr, Sarah , Barroso‐Gil, Miguel , Neatu, Ruxandra , Joli, Giancarlo, Dahl, Neera K. , Kline, Timothy L. , Jouret, François , Steinman, Theodore I., Watnick, Terry , Larson, Nicholas B. , Halbritter, Jan , Harris, Peter C. , Gastel, Maatje D.A. van , Jawaid, Tabinda , Ma, Jun , Audrézet, Marie-Pierre , Madsen, Charles D , Schauer, Rachel S , Baker, Tracy A , Gregory, Adriana V , Orr, Sarah E , Barroso-Gil, Miguel , Neatu, Ruxandra , Dahl, Neera K , Kline, Timothy L , Gillion, Valentine , Jouret, Francois , Torres, Vicente E , Peters, Dorien J M , Gitomer, Berenice Y , Watnick, Terry J , Chebib, Fouad T , Hogan, Marie C , Olson, Janet E , Larson, Nicholas B , Ars, Elisabet , Halbritter, Jan , Demoulin, Nathalie , Torres, Vicente E , Sayer, John A , Cornec-Le Gall, Emilie , Harris, Peter C , Senum, Sarah R , Elbarougy, Doaa E , Buia, Guillaume, McDonnell, Shannon K. , Dahan, Karin , Perrone, Ronald D. , Peters, Dorien J.M. , Coto, Eliécer , Chebib, Fouad T. , Hogan, Marie C. , Olson, Janet E. , Torres, Vicente E. , Gall, Émilie Cornec-Le

Mayo Clinic

Journal of the American Society of Nephrology | February 3, 2025 | Volume: 36 | Issue: 6 | Pages: 1056-1071

10.1681/asn.0000000613 | PMID 39899384 Get It

Key Points Loss-of-function ALG8 and ALG9 variants were enriched in polycystic kidney/liver groups and International Classification of Diseases–coded cystic individuals in population cohorts. The ALG8 and ALG9 kidney phenotypes were usually mild to moderate, and lower eGFR or kidney failure was rare. ALG8 pathogenic variants sometimes resulted in severe polycystic liver disease. Background Autosomal dominant polycystic kidney disease (ADPKD) is a common, inherited nephropathy often resulting in kidney failure. It is genetically heterogeneous; along with the major genes, PKD1 and PKD2 , at least eight others have been suggested. ALG8 pathogenic variants have been associated with autosomal dominant polycystic liver disease and implicated in ADPKD, while ALG9 has been suggested as an ADPKD gene, but details of the phenotypes and penetrance are unclear. Methods We screened >3900 families with cystic kidneys and/or livers using global approaches to detect ALG8 or ALG9 pathogenic variants. In addition, population cohorts with sequence data (Genomics England 100K Genomics Project, UK Biobank, and Mayo Clinic Biobank [MCBB]) were screened for ALG8 / ALG9 pathogenic variants. Results Multicenter screening of individuals with polycystic kidney and/or liver disease identified 51 (1.3%) ALG8 (7 multiplex) and 23 (0.6%) ALG9 (5 multiplex) families—frequencies that were approximately 10× and approximately 24× greater than nonpolycystic kidney disease controls. Analysis of individuals with polycystic kidney disease phenotypes in 100K Genomics Project, UK Biobank, and MCBB identified nine ALG8 (0.39%) and nine ALG9 (0.39%) families, an enriched frequency over controls. Two individuals had PKD1 and ALG8 pathogenic changes. Eighty-nine percent of individuals with ALG8 mutations with imaging in the entire MCBB had kidney cysts (50%, >10 cysts), with greater median kidney and liver cyst numbers than controls. For ALG9, 78% had kidney cysts (27%, >10 cysts). Individuals with ALG8 mutations typically had mild cystic kidneys with limited enlargement. Liver cysts were common (71%), with enlarged livers (>2L) found in 11 of 62 patients, although surgical intervention was rare. The ALG9 kidney phenotype was also of mild cystic kidneys, but enlarged livers were rare; for both genes, CKD or kidney failure were rare. Conclusions ALG8 and ALG9 are defined as cystic kidney/liver genes but with limited penetrance for lower eGFR.
Impact of smoking on recurrence rates among wide-neck intracranial aneurysms treated with Woven EndoBridge: a multicenter retrospective study
Vaishnav, Dhrumil , Adeeb, Nimer , Aslan, Assala , Cancelliere, Nicole M., McLellan, Rachel , Ghozy, Sherief, Lay, Sovann V. , Guenego, Adrien , Premat, Kévin , Möhlenbruch, Markus, Kral, Michael , Doron, Omer , Salem, Mohamed M. , Foreman, Paul M. , Vachhani, Jay A. , Shaikh, Hamza, Župančić, Vedran , Ayberk, Gıyas , Güneş, Yasin Celal , Rabinov, James D. , Ren, Yifan , Michelozzi, Caterina , Elens, Stéphanie , Starke, Robert M., Hassan, A. , Ogilvie, Mark , Nguyên, Anh , Jones, Jesse , Brinjikji, Waleed , Nawka, Marie Teresa , Psychogios, Marios, Ulfert, Christian , Diestro, Jose Danilo Bengzon , Pukenas, Bryan , Burkhardt, Jan‐Karl , Martinez-Gutierrez, Juan Carlos, Sheth, Sunil G. , Spiegel, Gary, Lubicz, Boris , Puri, Ajit S., Pero, Guglielmo , Nossek, Erez , Raz, Eytan, Griessenauer, Christoph J., Asadi, Hamed , Siddiqui, Adnan, Brook, Allan , Haranhalli, Neil , Ducruet, Andrew F. , Albuquerque, Felipe C. , Regenhardt, Robert W. , Stapleton, Christopher J. , Kan, Peter, Kalousek, Vladimir , Lylyk, Pedro , Boddu, Srikanth , Knopman, Jared , Tjoumakaris, Stavropoula I., Clarençon, Frédéric, Cuellar-Saenz, Hugo H., Patel, Aman B. , Altschul, David , _, _, Spears, Julian , Sundararajan, Sri Hari , Balush, Ali Al, Inoue, Yasuaki , Mirshahi, Shervin , Harker, Pablo, Tutino, Vincent M., Brehm, Alex , Diestro, Jose Danilo B , Shotar, Eimad , Nguyen, Anh , Pero, Guglielmo , Kalousek, Vladimir , Altschul, David J , Regenhardt, Robert W , Ulfert, Christian , Lay, Sovann V , Essibayi, Muhammed Amir , Musmar, Basel , Salim, Hamza , Cancelliere, Nicole M , Algin, Oktay , Ghozy, Sherief , Renieri, Leonardo , Carnevale, Joseph Anthony , Saliou, Guillaume , Mastorakos, Panagiotis , Naamani, Kareem El , Shotar, Eimad , Möhlenbruch, Markus , Chung, Charlotte , Lylyk, Iván , Hafeez, Muhammad Ubaid , Catapano, Joshua S , Waqas, Muhammad , Schirmer, Clemens M. , Piano, Mariangela , Kühn, Anna Luisa , Hassan, Ameer E , Psychogios, Marios‐Nikos , Huynh, Thien , Martinez-Gutierrez, Juan Carlos , Sheth, Sunil A., Tawk, Rabih G. , Panni, Pietro , Puri, Ajit S , Raz, Eytan , Killer-Oberpfalzer, Monika , Griessenauer, Christoph J. , Aziz‐Sultan, Mohammad Ali , Tjoumakaris, Stavropoula , Clarençon, Frédéric , Limbucci, Nicola , Cuellar, Hugo , Jabbour, Pascal , Mendes Pereira, Vitor , Dmytriw, Adam A. , _, _, Dibas, Mahmoud , Vranic, Justin E. , Alotaibi, Naif M. , Harker, Pablo , Sporns, Peter Bernhard

Mayo Clinic

Journal of Neurosurgery | January 31, 2025 | Volume: 142 | Issue: 6 | Pages: 1732-1740

10.3171/2024.10.jns241058 | PMID 39889291 Get It

OBJECTIVE Tobacco smoking is among the factors known to significantly augment the risk of untreated intracranial aneurysm (IA) growth and rupture. Smoking appears to have a variable effect on different endovascular treatment modalities. The impact of smoking on the safety, efficacy, and outcomes of Woven EndoBridge (WEB) device use for wide-neck IAs has not been evaluated. This study aimed to investigate the outcomes of WEB devices by smoking status. METHODS A retrospective multicenter analysis was conducted on the data of patients from 36 sites worldwide treated with the WEB device for intracranial saccular aneurysms. Patients were stratified based on smoking status (current, former, and never smokers). The Student t-test and chi-square test were performed for continuous and categorical variables, respectively. Multivariable logistic regression was used to adjust for confounders. RESULTS Of 1376 patients with available smoking status, 504 were current smokers, 358 were former smokers, and 514 were never smokers. Upon adjusting for significant confounders, no association was found between smoking and recurrence outcomes (OR 1.39, 95% CI 0.69–2.80; p = 0.36), thromboembolic and hemorrhagic complications, and mortality among IAs treated with the WEB device. There was no statistically significant difference in outcomes between former and never smokers (OR 1.23, 95% CI 0.70–2.18; p = 0.46). The location of aneurysms differed between smoking groups, with former smokers having more anterior circulation aneurysms compared with current and never smokers (99.0% vs 96.9% vs 95.3%; p = 0.01). In terms of clinical symptoms, headache and dizziness were more common in the never smokers compared with current and former smokers (13.9% vs 8.9% vs 7.7%, p = 0.01). CONCLUSIONS This large-scale study suggests no significant correlation between smoking and the recurrence of IAs treated with the WEB device. Biological studies are warranted to better understand the biological impact of smoking on the growth and rupture of treated IAs.
982: EXTERNAL VALIDATION OF THE FRASER EQUATION TO ESTIMATE FREE VALPROATE CONCENTRATION IN THE ICU
Brown, Caitlin S. , Liu, JiTong , Riker, Richard R. , Lopez, Natasha , Gagnon, David J. , Webb, Andrew , Rosenthal, Eric S.

Mayo Clinic

Critical Care Medicine | January 31, 2025 | Volume: 53 | Issue: 1 | Pages: No page available

10.1097/01.ccm.0001102592.08813.34 Get It